Building America's Premier Health Innovation Platform: eMerge Americas' Cross-Sector 

Join host Megan Antonelli as she sits down with Melissa Medina, Co-Founder & CEO of eMerge Americas, to discuss the landmark partnership that's reshaping healthcare innovation. From transforming Miami into a global tech hub to launching the most dynamic health platform in the Americas, Melissa shares insights on cross-sector collaboration, venture capital trends, and why Florida is becoming the epicenter for breakthrough healthcare solutions. Discover how eMerge HEALTH 2026 will unite payers, providers, policymakers, and innovators to drive real-world impact across AI, precision health, and health equity initiatives.

Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Digital Health Talks: Building America's Premier Health Innovation Platform

Host Gary J. Ross speaks with Erik Syvertsen, Chief Legal Officer of AngelList. After a brief introduction, Erik starts off the chat by outlining some of AngelList’s key offerings, including SPVs, Rolling Funds, and Roll Up Vehicles. Gary and Erik then go into how AngelList funds tend to be structured, as well as how AngelList navigates regulatory concerns such as general solicitation and the investment adviser and broker-dealer rules. The episode concludes with a conversation about regulatory trends affecting the platform and the broader venture capital ecosystem, including potential initiatives to expand VC access to retail investors.

VC Law: Episode 39: A Talk with Erik Syvertsen, Chief Legal Officer of AngelList

M.A.L.T.E.G.A.-  Back to My Ways (Ft SleezyBundles) (2025)

Investing in Heart Health Innovation: A Conversation with Forbes 50 Over 50 Honoree Lisa Suennen of AHA Ventures

Welcome to today's episode where we have the distinct privilege of speaking with Lisa Suennen, Managing Partner of American Heart Association Ventures, who was just featured in Forbes 50 Over 50 and we couldn't be more thrilled to congratulate her on this well-deserved recognition! This honor celebrates Lisa's extraordinary impact as a true powerhouse in healthcare innovation and venture capital. With over 35 years of experience at the intersection of healthcare, technology, and investment, Lisa brings an unparalleled perspective on how we can transform healthcare delivery and outcomes. At American Heart Association Ventures, she leads a multi-fund platform that's investing in the future of healthcare across the entire spectrum—from cutting-edge medical technologies to addressing critical social determinants of health. 

Her career has spanned multiple dimensions of the healthcare ecosystem:

   • Venture Capital Leadership: From her current role at AHA Ventures to previous General Partner positions at Manatt Ventures, Psilos Group, and GE Ventures, where she led the healthcare fund and served on the overall Investment Committee
   • Entrepreneurial Success: Co-founded and served as CEO of CSweetener, a healthcare leadership development company that was successfully acquired by HLTH Foundation
   • Strategic Advisory Roles: Chairs the Scientific Advisory Board of NASA's Translational Research Institute for Space Health and serves on the International Investment Committee of the ANDHealth Digital Health Fund
   • Thought Leadership: Author of the widely-read Venture Valkyrie blog, internationally recognized speaker, and faculty member at UC Berkeley's Haas School of Business
   • Industry Recognition: Fellow of the prestigious Aspen Institute's Health Innovators Fellowship

Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Digital Health Talks: Investing in Heart Health Innovation In A Conversation with Forbes 50 Over 50

Host Gary J. Ross speaks with Ruth Jin, Partner at Mintz Levin, about GP-led secondary transactions, in which a general partner of a fund initiates a sale of one (or more) of its portfolio companies to a new fund, called a continuation vehicle (CV), which is typically managed by the same GP. Ruth describes the setting up and marketing of the continuation vehicle, and the options given to the current fund’s limited partners. Gary and Ruth spend significant time on the conflict of interest issues, and how they are mitigated. Ruth also touches on the necessary disclosures that must be made in the CV’s offering documents.

VC Law: Episode 40: GP-Led Secondary Transactions with Ruth Jin, Partner at Mintz Levin

전통적 벤처캐피털이 점점 더 신중하고 선별적인 투자 성향으로 변하면서 바이오 기업들이 새로운 자본 조달 경로를 모색하고 있다는 Citeline의 In Vivo 기사를 요약한 내용입니다.

https://insights.citeline.com/in-vivo/growth/when-vc-steps-back-finding-alternative-biotech-funding-4UN5IYJEUZD2XPLYIZ7RR7YVQY/

 Playlist: https://soundcloud.com/citelinesounds/sets/korean-language-biopharma-mini

VC가 한발 물러설 때 바이오 기업의 대체 자금원은? (Korean-language podcast)

Host Gary J. Ross talks with Chris Harvey, Managing Partner at Harvey Esquire and a prolific LinkedIn contributor, about three bipartisan bills pending in Congress that could reshape the VC ecosystem: the Equal Opportunity for All Investors Act (HR 3339), which would create an exam-based path to accredited investor status; the Improving Capital Allocation for Newcomers Act (HR 4431), which would raise Section 3(c)(1) fund limits to 500 investors and $50 million; and the Venture Capital Advisor Flexibility Act (HR 4429), which would increase the allowable percentage of secondaries and fund-of-funds investments for exempt reporting advisers.

VC Law: Episode 41: Pending VC-Friendly Legislation with Chris Harvey

Os fundos de venture capital não só investem pesado em teses de inteligência artificial. A tecnologia pode mudar como as gestoras escolhem suas apostas. Mas o “olho no olho” ainda será relevante, defende Daniel Ibri, da Mindset Ventures

#15 - Daniel Ibri, sócio-fundador da Mindset Ventures

After two of the toughest years in biotech history, are we finally seeing a turnaround? EY's Arda Ural discusses the long-awaited recovery in biotech IPOs, the evolving capital markets landscape and how tariffs and Trump RX are reshaping biopharma supply chains.
 
In this wide-ranging conversation, Ural unpacks the three key factors driving IPO recovery — Fed rate cuts, improving valuations, and reduced macro uncertainty — while sharing hard data on what's actually working in 2024. He explains why platforms without products are struggling to raise venture capital, how the bid-ask spread in M&A deals reflects ongoing valuation disagreements and why China's emergence as a competitor in novel drug development represents a fundamental shift for the industry.
 
Whether you're navigating early-stage financing, preparing for an IPO, or planning strategic transactions, this episode delivers actionable insights on capital markets, policy impacts and the fundamentals that will determine who succeeds in the next phase of biotech innovation.

EY's Arda Ural on IPOs, Financial Markets and Tarrifs

Season 2 Episode #4: In this episode of Tech Effect, we meet Ģirts Graudiņš: A Latvian-American technology entrepreneur, who is an expert in building and running engineering teams at Silicon Valley startups as well as an active investor in the Baltic early-stage startup ecosystem - individually, as a Venture Partner at Change Ventures, and an Investment Committee member at BADideas.fund. Join us as Ģirts takes us through his journey, gives insights into the what and how a startup can break out of its local market, how smaller startups can gain a competitive edge, and what KPIs to look for.


👉 Hit "Follow" on our podcast page to receive updates on future episodes of "Tech Effect," where we bring you the latest news, trends, and expert insights from the world of technology. Together, let's unlock the potential of software solutions and embrace the future of innovation. 


🔔 Follow TestDevLab for more technology & software related content:
LinkedIn: https://www.linkedin.com/company/testdevlab/
Facebook: https://www.facebook.com/TestDevLab/
Instagram: https://www.instagram.com/testdevlablv/#TechEffect 

# 23 Ģirts Graudiņš (Ex-Twilio, Investor & Expert): Breaking Into US & Global Markets As A Startup

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

O programa Revolução IA terá periodicidade quinzenal e receberá desde CEOs, CIOs e CTOs de grandes empresas aos principais especialistas do tema para debater como a inteligência artificial pode sacudir o mundo empresarial e discutir todos os desafios do ecossistema, passando por infraestrutura e data centers até as questões éticas e legais da tecnologia

TestDevLab's Tech Effect is a podcast where host Josh explores software engineering and tech innovation through conversations with diverse industry professionals. Covering testing, development, and emerging trends, each episode delivers insights valuable for both technical and business roles—ideal for anyone interested in technology's impact across industries.

RADIO FOR THE HEALTHCARE INDUSTRY
Healthcare NOW Radio and Podcast Network offers discussions on the latest developments and trends impacting the industry including: health tech, health IT, healthcare innovation, healthcare policy, healthcare data security, telehealth, interoperability, biotech, med tech, value-based care, pharma, healthcare compliance, and much more. Shows are hosted by industry thought leaders. Guests are a "who's who" across the healthcare spectrum.  The listening audience is predominantly physician and hospital-based, and the healthcare industry at large.

New tracks tagged #VentureCapital